Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$107.20 USD

107.20
53,353

-0.89 (-0.82%)

Updated Jul 30, 2024 11:17 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

by Zacks Equity Research

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

by Zacks Equity Research

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable

by Zacks Equity Research

Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.

Masimo (MASI) Down 1.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

by Zacks Equity Research

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 3.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study

by Zacks Equity Research

Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Debanjana Dey headshot

Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on

by Debanjana Dey

Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

by Zacks Equity Research

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

by Zacks Equity Research

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

Masimo (MASI) Strengthens Global Footprint With New Launch

by Zacks Equity Research

Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.

Masimo (MASI) Up 6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study

by Zacks Equity Research

Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.

Masimo (MASI) Bridge Hailed as Opioid Substitute in New Study

by Zacks Equity Research

Masimo's (MASI) Bridge device is likely to allow more patients to be benefited by auriculotherapy, thereby reducing the possibility of opioid overuse.

Here's Why Momentum in Masimo (MASI) Should Keep going

by Zacks Equity Research

Masimo (MASI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.

Masimo (MASI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?